NA
CUE icon

NewEdge Advisors’s Cue Biopharma CUE Stock Holding History

NewEdge Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.6K Hold
667
– – ﹤0.01% 3618
2025
Q4 		$6.11K Hold
667
– – ﹤0.01% 3620
2025
Q3 		$14.4K Hold
667
– – ﹤0.01% 3236
2025
Q2 		$13.6K Buy
667
+582
+685% +$12.4K ﹤0.01% 3091
2025
Q1 		$2.32K Hold
85
– – ﹤0.01% 3478
2024
Q4 		$2.78K Hold
85
– – ﹤0.01% 3387
2024
Q3 		$1.93K Hold
85
– – ﹤0.01% 3388
2024
Q2 		$3.16K Buy
+85
New +$4.2K ﹤0.01% 3228

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

NewEdge Advisors's CUE Position: Q1 2026 in Review

NewEdge Advisors held its Cue Biopharma (CUE) position steady in Q1 2026 at 667 shares worth $4.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3618.

NewEdge Advisors first reported a position in CUE in Q2 2024 and has held it in 8 quarters since. The position peaked at $14.4K in Q3 2025. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • NewEdge Advisors held 667 shares of Cue Biopharma worth $4.6K as of Q1 2026.
  • NewEdge Advisors left its Cue Biopharma share count unchanged in Q1 2026.
  • Cue Biopharma made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3618 holding.
  • NewEdge Advisors first reported a position in Cue Biopharma in Q2 2024 and has held it in 8 quarters since.
  • NewEdge Advisors's Cue Biopharma position peaked at $14.4K in Q3 2025.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.